The DOI matches its Crossref record; 85 of the 87 references it cites were found in a registry or an index.
Drug repurposing: a promising tool to accelerate the drug discovery process
Open accessAbstract
Traditional drug discovery and development involves several stages for the discovery of a new drug and to obtain marketing approval. It is necessary to discover new strategies for reducing the drug discovery time frame. Today, drug repurposing has gained importance in identifying new therapeutic uses for already-available drugs. Typically, repurposing can be achieved serendipitously (unintentional fortunate observations) or through systematic approaches. Numerous strategies to discover new indications for FDA-approved drugs are discussed in this article. Drug repurposing has therefore become a productive approach for drug discovery because it provides a novel way to explore old drugs for new use but encounters several challenges. Some examples of different approaches are reviewed here.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These tools can identify ligands, decode drug ingredient binding schemas, and highlight promising candidates from an expansive list of potential compounds.27,31,32”
From Drug repurposing for cancer therapy (2024) · cites this paper as [27]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drug repurposing: progress, challenges and recommendations
Pushpakom, S., Iorio, F., Eyers, P. A., Escott, K. J., Hopper, S., Wells, A., Doig, A., Guilliams, T., Latimer, J., McNamee, C., et al. (2019) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.168 · Cited by 4,718
Drug repositioning: identifying and developing new uses for existing drugs
Ashburn, T. T., & Thor, K. B. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1468 · Cited by 3,237
Chong, C. R., & Sullivan, D. J. (2007) · Nature · doi:10.1038/448645a · Cited by 996
Opportunities and challenges in phenotypic drug discovery: an industry perspective
Moffat, J. G., Vincent, F., Lee, J. A., Eder, J., & Prunotto, M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.111 · Cited by 939
Rare cancers are not so rare: The rare cancer burden in Europe
Gatta, G., van der Zwan, J. M., Casali, P. G., Siesling, S., Tos, A. P. D., Kunkler, I. H., Otter, R., Licitra, L. F., Mallone, S., Tavilla, A., et al. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.08.008 · Cited by 813
Systematic integration of biomedical knowledge prioritizes drugs for repurposing
Himmelstein, D. S., Lizee, A., Hessler, C., Brueggeman, L., Chen, S. L., Hadley, D., Green, A., Khankhanian, P., & Baranzini, S. E. (2017) · eLife · doi:10.7554/elife.26726 · Cited by 666
Arrowsmith, J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3439 · Cited by 622
Polypharmacology: drug discovery for the future
Reddy, A. S., & Zhang, S. (2012) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.12.74 · Cited by 498
Phase III and submission failures: 2007–2010
Arrowsmith, J. E. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3375 · Cited by 480
Phenotypic screens as a renewed approach for drug discovery
Zheng, W., Thorne, N., & McKew, J. C. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.07.001 · Cited by 438
Flagged first, then by citations
2 of the 87 references couldn’t be matched to a known paper.
Research works printed but not linked: 2
- Repurposing drugs helps patients with rare diseases. Available at: https://www.elsevier.com/connect/repurposing-drugs-helps-patients-with-rare-diseases.
- Sekhon, 2013, Repositioning drugs and biologics: retargeting old/existing drugs for potential new therapeutic applications, J. Pharm. Educ. Res., 4, 1
Cited by
Sorted by citations
Artificial intelligence in cancer target identification and drug discovery
You, Y., Lai, X., Pan, Y. F., Zheng, H., Vera, J., Liu, S., Deng, S., & Zhang, L. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00994-0 · Cited by 499
“It refers to a method that identi fi es new indications for approved drugs or drug candidates which have failed in the development phase 232 .”
MethodDrug repurposing for cancer therapy
Xia, Y., Sun, M., Huang, H., & Jin, W.-L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01808-1 · Cited by 443
“27,28 More often, these techniques are synergistically utilized.”
BackgroundMethodDrug Repurposing: An Effective Tool in Modern Drug Discovery
Kulkarni, V. S., Alagarsamy, V., Solomon, V. R., Jose, P. A., & Murugesan, S. (2023) · Russian Journal of Bioorganic Chemistry · doi:10.1134/s1068162023020139 · Cited by 264
Pillaiyar, T., Meenakshisundaram, S., Manickam, M., & Sankaranarayanan, M. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112275 · Cited by 140
“This means the success rate of drug approval is so high when compared to the traditional methods [202].”
ResultUtilizing drug repurposing against COVID-19 – Efficacy, limitations, and challenges
Parvathaneni, V., & Gupta, V. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118275 · Cited by 138
“Apart from serendipitous observations, drug repurposing can be executed through several strategies including binding assays and phenotypic screening methods or computational methods, as presented in Table 1 [23].”
InfluentialSelf-citation
Metadata
- Authors
- Parvathaneni, V., Kulkarni, N. S., Muth, A., & Gupta, V.
- Affiliations
- St. John's University (US)
- Corresponding author
- Gupta, Vivek
- Venue
- Drug Discovery Today
- Publisher
- Elsevier BV
- Published
- 2019-10
- Volume
- 24
- Issue
- 10
- Pages
- 2076-2085
- ISSN
- 1359-6446 (ISSN-L)
- PMC
- PMC11920972
- OpenAlex
- W2951512731
- Semantic Scholar
- 023e169dfa4fe591ef24cf91b93e0d7371bb3400
- Cited by
- 597
- References
- 87
- Citations by year
- 2026: 80 · 2025: 137 · 2024: 130 · 2023: 96 · 2022: 77 · 2021: 52 · 2020: 22 · 2019: 3
- FWCI
- 3.18
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Drug Discovery Today (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Figshare (submittedVersion, cc-by)
- Health Research Alliance (cc-by)
- Funders
- NIH (1R15HL138606-01A1)
- American Heart Association (18AIREA33960072)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Health Sciences › Medicine › Pharmacology (medical) › Historical Medical Research and Treatments
- Keywords
- drug repurposing, FDA-approved drugs, new therapeutic indications, serendipitous drug discovery, drug development challenges
- MeSH terms
- Humans, Drug Discovery, Drug Repositioning
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
